Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3745 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Gerald Chun-To So und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Pharmacokinetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Eli Lilly and Company, NIH HHS.
Abstract (Originalsprache)
The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies. Baseline data from seven renal impairment studies were pooled to estimate the impact of three creatinine‐based equations (Cockcroft‐Gault, CKD‐EPI 2009 , and absolute CKD‐EPI 2009 ) on classification of participants into different renal impairment categories. Retrospective analyses were performed on two renal impairment studies with three distinct analytes (predominantly renally cleared; and predominantly metabolized by hepatic cytochrome P450 enzymes, or by systemic peptidase) using regression or categorical statistical analysis methods and creatine‐based equations. While the three equations were highly correlated, the use of a different equation may result in up to 50% of participants being reclassified into different renal impairment groups. Categorical analysis with analysis of variance provided different point estimates and precision of exposure difference for a given renal impairment group based on the equation used. The use of regression analysis without inclusion of data from participants on hemodialysis, as recommended by the Food and Drug Administration, showed most consistent estimate of the relationship between renal impairment and exposure of three analytes. These retrospective analyses support the Food and Drug Administration recommendations of using regression analysis without data from participants on hemodialysis as the primary analysis of data for renal impairment study; and established a modeling strategy for such analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Gerald Chun-To So, Jenny Chien, Christopher D Payne, Maria M Posada, Yan Jin
Förderung
- NIGMS NIH HHS
- Eli Lilly and Company
- NIH HHS
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
So, G. C., Li, Y. G., Hall, S. D., Chien, J., Payne, C. D., Posada, M. M., Piruzeli, M. L. B., & Jin, Y. (2025). Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3745
Vancouver
So GC, Li YG, Hall SD, Chien J, Payne CD, Posada MM, et al. Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3745
BibTeX
@article{So2025,
author = {So, Gerald Chun-To and Li, Ying Grace and Hall, Stephen D and Chien, Jenny and Payne, Christopher D and Posada, Maria M and Piruzeli, Maria Lucia Buziqui and Jin, Yan},
title = {Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3745}
}
EUVIMED